-
New first-in-class cholesterol-lowering treatment NILEMDO® and its combination with ezetimibe NUSTENDI® approved in EuropeDaiichi Sankyo2020-08-03 09:23:48New first-in-class cholesterol-lowering treatment NILEMDO® and its combination with ezetimibe NUSTENDI®
-
Phase 2 DESTINY-Gastric01 Trial of DS-8201 Versus Chemotherapy Met Primary EndpointDaiichi Sankyo2020-01-27 09:31:00Phase 2 DESTINY-Gastric01 Trial of DS-8201 Versus Chemotherapy Met Primary Endpoint
